β-Amyloid (1-40) (human), mAb (5C3)



ALX-804-410-C100	100 µg	259.00 USD

Replaces Prod. #: ADI-905-802

Product Specification

Purity Detail:	Purified from serum-free cell culture supernatant by subsequent thiophilic adsorption and size exclusion chromatography.

Formulation:	Lyophilized from 1ml 2x PBS, 0.09% sodium azide, PEG and sucrose.

Clone:	5C3

Isotype:	Mouse IgG1

Immunogen:	Synthetic peptide corresponding to aa 1-40 of human β-amyloid.

Reconstitution:	Reconstitute with 1ml water (15min, RT).

Specificity:	Recognizes human β-amyloid (aa 1-40). Does not cross-react with β-amyloid (aa 1-42).

Application:	ELISA (0.1 μg/ml) Immunocytochemistry (1-10µg/ml) Western Blot (1µg/ml for HRPO/ECL detection) Recommended blocking buffer: Casein/Tween 20 based blocking and blot incubation buffer.

Short Term Storage:	+4°C

Long Term Storage:	-20°C

Use/Stability:	For long-term storage, freeze lyophilizate upon arrival (-20°C). Reconstituted antibody is stable for 1 year when stored at -80°C. Thaw aliquots at +37°C. Thawed aliquots may be stored at +4°C for up to 3 months.

Handling:	After reconstitution, prepare aliquots and freeze in liquid nitrogen. Avoid freeze/thaw cycles.

Miscellaneous/General:	The beta-amyloid peptide (beta A4), proteolytically released from the amyloid precursor protein (APP), is the principal component of senile plaques in Alzheimer's disease. Cleavage of APP by alpha-secretase or alternatively by beta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, respectively, and the retention of corresponding membrane-anchored C-terminal fragments, C83 and C99. Subsequent processing of C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is nonamyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59).

Product Literature References

Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice: B. Liu, et al.; Am. J. Pathol. 175, 2099 (2009), Abstract;